VTVT vTv Therapeutics Inc.

Nasdaq vtvtherapeutics.com


$ 29.25 $ 1.11 (3.97 %)    

Tuesday, 11-Nov-2025 15:59:39 EST
QQQ $ 624.44 $ 0.00 (0 %)
DIA $ 480.14 $ 0.00 (0 %)
SPY $ 684.67 $ 0.00 (0 %)
TLT $ 89.64 $ 0.00 (0 %)
GLD $ 379.80 $ 0.00 (0 %)
$ 29.1
$ 28.14
$ 14.00 x 100
$ 30.63 x 7
-- - --
$ 12.80 - $ 33.06
13,516
na
114.6M
$ 1.17
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-12-2025 06-30-2025 10-Q
3 05-15-2025 03-31-2025 10-Q
4 03-20-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-13-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-11-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-06-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-15-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-29-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-04-2021 06-30-2021 10-Q
19 05-05-2021 03-31-2021 10-Q
20 02-24-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-03-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 02-21-2020 12-31-2019 10-K
25 10-30-2019 09-30-2019 10-Q
26 07-31-2019 06-30-2019 10-Q
27 05-01-2019 03-31-2019 10-Q
28 02-26-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-03-2018 06-30-2018 10-Q
31 05-15-2018 03-31-2018 10-Q
32 02-27-2018 12-31-2017 10-K
33 11-01-2017 09-30-2017 10-Q
34 08-02-2017 06-30-2017 10-Q
35 05-03-2017 03-31-2017 10-Q
36 02-24-2017 12-31-2016 10-K
37 11-03-2016 09-30-2016 10-Q
38 08-02-2016 06-30-2016 10-Q
39 05-13-2016 03-31-2016 10-Q
40 03-04-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 vtv-therapeutics-q3-eps-108-misses-098-estimate

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(...

 hc-wainwright--co-reiterates-buy-on-vtv-therapeutics-maintains-36-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates vTv Therapeutics (NASDAQ:VTVT) with a Buy and maintains $36 price ta...

 vtv-therapeutics-q2-eps-092-misses-082-estimate

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(...

 vtv-therapeutics-announces-first-participant-has-been-randomized-in-its-phase-3-catt1-trial-evaluating-cadisegliatin-as-an-adjunctive-oral-treatment-to-insulin-in-adults-with-type-1-diabetes

vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small mole...

 vtv-therapeutics-appoints-michael-tung-as-evp-and-cfo-effective-immediately

vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M...

 vtv-therapeutics-q1-eps-077-beats-092-estimate

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0....

 hc-wainwright--co-initiates-coverage-on-vtv-therapeutics-with-buy-rating-announces-price-target-of-36

HC Wainwright & Co. analyst Emily Bodnar initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy rating and anno...

 vtv-therapeutics-q4-2024-gaap-eps-055-beats-087-estimate

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0....

 fda-lifts-clinical-hold-on-vtv-therapeutics-phase-3-diabetes-trial-stock-surges

vTv Therapeutics' Phase 3 trial for cadisegliatin in type 1 diabetes resumes after FDA lifts hold, with a revised six-month...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION